South Korean pharmaceutical firm Green Cross announced on Friday that the Ministry of Food and Drug Safety has approved its investigational new drug application for Phase 2 and 3 clinical trials of GC3114B, a high-immunogenicity influenza vaccine candidate. The trials aim to evaluate the vaccine’s safety and immune response in adults aged 65 and older.
GC3114B is engineered with a higher antigen content than standard-dose flu vaccines to address the natural decline in immune function associated with aging. According to Green Cross, the company plans to administer the first doses for the Phase 2 trial in the second half of this year, with the subsequent Phase 3 study designed as a multinational effort to support future global market expansion.
The move comes as South Korea faces an aging demographic, prompting the Korea Disease Control and Prevention Agency to evaluate the potential inclusion of high-immunogenicity vaccines in its National Immunization Program. Currently, such vaccines are primarily imported. Green Cross is working to establish a domestic supply chain, having signed a memorandum of understanding with Korea Vaccine in July to utilize prefilled syringe production facilities for future manufacturing.
Lee Jae-woo, head of the development division at Green Cross, stated that the company intends to target regulatory approval within three years. By leveraging its existing research and production infrastructure, the firm seeks to reduce reliance on foreign-made high-immunogenicity products while enhancing its overall competitive standing in the vaccine market.
Follow-up Questions
What is the primary difference between GC3114B and standard flu vaccines?
GC3114B contains a higher concentration of antigen, which is designed to elicit a more robust immune response in older adults whose natural immune function may be diminished
What remains unclear: The exact antigen dosage difference compared to standard vaccines was not disclosed in the initial report
Will GC3114B be covered by South Korea's National Immunization Program?
The Korea Disease Control and Prevention Agency is currently reviewing whether to include high-immunogenicity flu vaccines in the national program
What remains unclear: The final decision and timeline for inclusion remain under government review
Perspectives
Green Cross Management vs Public Health Regulators
Story lens
Green Cross Management
The company views the development of GC3114B as a strategic move to boost business competitiveness by localizing production of high-demand vaccines. By initiating multinational trials, Green Cross aims to secure a foothold in both domestic and international markets, shifting away from reliance on imports
Public Health Regulators
The Korea Disease Control and Prevention Agency faces the challenge of adapting national immunization strategies to a rapidly aging society. Their evaluation of high-immunogenicity vaccines reflects a broader policy shift toward specialized preventive care for the elderly to reduce the burden of seasonal influenza
Middlesbrough schools shut early as surge police deploy to prevent potential unrest ahead of the funeral for a victim of the fatal A66 head-on collision.
As Labor Day 2026 marks 17 years of a frozen $7.25 federal minimum wage, over 12 million US workers earn under $15 an hour amid eroded purchasing power.
The 53rd Telluride Film Festival revealed its lineup of over 60 features, led by world premieres like Andrew Scott’s Elsinore and Jesse Eisenberg’s The Debut.
London City Lionesses owner Michele Kang has secured a landmark front-of-shirt Nike partnership that redefines independent commercial value in women’s football.
A joint summer holiday in the South of France highlights the delicate balance between public co-parenting and the private logistical realities of separation.
